The most frequent TEAEs among telitacicept-treated patients were upper respiratory tract infection (42.5 vs 32.7% with placebo), decreased blood immunoglobulin (Ig)G (16.2 vs 1.8%) or IgM (15.6 vs 0.6%), injection site reactions (12.6 vs 0.6%), and urinary tract infection (11.4 vs 15.5%).

One patient experienced a urinary tract infection and there were no cases of diabetic ketoacidosis.

He said that there was “no signal” for increased rates of serious infections, herpes zoster, or COVID-19 with deucravacitinib treatment, but there were higher rates of urinary tract infections in the TYK inhibitor versus placebo arms (6.5–11.0 vs 3.3%), as well as a signal for skin-related adverse events (16.5–34.4 vs 13.3%).

In all, 91% of obinutuzumab-treated patients and 89% of those given placebo experienced adverse events during 2 years of follow-up, most commonly urinary tract infections in both groups (23 vs 21%).

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

Overall rates of AEs, serious AEs, and AEs leading to treatment discontinuation in SELECT-PsA 2 Most frequent AEs The most commonly reported treatment-emergent AEs occurring in at least 5% of patients in either upadacitinib group were: upper respiratory tract infection; nasopharyngitis; bronchitis; urinary tract infection; influenza; diarrhea; nausea; and increase in blood creatine phosphokinase levels.

Pneumonia, urinary-tract, and surgical-site infections were the most common infections that occurred after surgery, occurring in 7–12%, 9–15%, and 3–19%, respectively, of the surgical groups.

The rate of serious infections requiring hospitalization, particularly sepsis, is increasing among people with gout, US longitudinal study data show.

The most frequently occurring infections were of the urinary tract (18.3%), followed by upper respiratory tract infections (17.2%) and nasopharyngitis (8.6%).

Serious infections resulting in hospitalization occurred within 30 days of knee or hip replacement in 9.0% of 7929 procedures in the Medicare dataset and 4.7% of 2994 procedures in MarketScan, most frequently urinary tract infection (4.1% overall), skin and soft tissue infection (1.1%), and pneumonia (0.9%), while prosthetic joint infections (PJI) occurred within 1 year of 2.0–2.6% of operations.

Post therapy, she developed a urinary tract infection, which was treated successfully with amoxicillin/clavulanic acid for 10 days.

The most frequently occurring AEs of any grade were injection site reactions and pain, urinary and upper respiratory tract infections, and diarrhea.

The most common adverse events occurring across all treatment groups were upper respiratory tract infections, alanine aminotransferase elevation, nasopharyngitis, urinary tract infections, and nausea.

One patient from Romania died from tuberculosis and this was considered possibly related to FKB327 treatment, otherwise the adverse events were as expected for adalimumab, such as respiratory tract infections and urinary tract infections, and low in numbers.

Indeed, the most common serious infections that have been reported with tofacitinib include pneumonia, cellulitis, herpes zoster, and urinary tract infection, and the prescribing information recommends that patients should be monitored for the development of any signs or symptoms of infection, or laboratory abnormalities that could lead to early identification of infection, during treatment with tofacitinib [12, 13].

Results of a real-world study suggest that recurrent infections occur frequently among treated patients with rheumatoid arthritis, and that the type of the initial infection is associated with subsequent infection risk.

In both the TNFI and DMARD groups, infections occurred most frequently in the respiratory tract (36.4 and 33.3%), followed by the digestive system (27.3 and 22.2%), other organ systems (18.2 and 22.2%), skin (9.1 and 16.7%), and the genitourinary system (9.1 and 5.6%).